The antirheumatic effect of benoxaprofen

Area of Science:

• Rheumatology
• Pharmacology
• Immunology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and systemic effects.
• Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for symptomatic relief in RA.
• Benoxaprofen is an NSAID investigated for its potential antirheumatic effects.

Purpose of the Study:

• To evaluate the antirheumatic activity of benoxaprofen in patients with rheumatoid arthritis.
• To assess the drug's impact on clinical disease activity and serological markers of inflammation.

Main Methods:

• A 6-month open-label trial involving 10 patients with definite or classic rheumatoid arthritis.
• Monthly assessments of clinical parameters (morning stiffness, walking time, joint tenderness/swelling, pain).
• Monthly monitoring of serological markers: rheumatoid factor (RF), C-reactive protein (CRP), alpha 1-antitrypsin, immunoglobulins (IgA, IgM, IgE), and erythrocyte sedimentation rate (ESR).

Main Results:

• Seven out of 10 patients showed clinical improvement in RA symptoms.
• Significant reductions in serum levels of RF, CRP, alpha 1-antitrypsin, IgA, IgM, and IgE were observed in the 7 responders.
• Erythrocyte sedimentation rates also decreased significantly in the improved group.
• Five initially seropositive patients became seronegative for RF; 5 of 6 with elevated CRP normalized levels.

Conclusions:

• Benoxaprofen exhibited antirheumatic properties in this patient cohort.
• The drug effectively reduced both clinical manifestations and key serological markers of inflammation in rheumatoid arthritis.
• Further controlled studies are warranted to confirm these findings and establish benoxaprofen's therapeutic role.